Startup News

Virex Pharma completes studies for its inhaled antiviral treatment

Picture of Joyce Guan
Joyce Guan
// // An important step in the road for the Freo-based biopharma, and the fight against diseases that afflict 3M children a year...

Fremantle-based biopharma Virex Pharma has announced the completion of in vitro studies for its Inhaled Antiviral Treatment for Respiratory Syncytial Virus (RSV).

RSV is a highly contagious respiratory virus that worldwide affects 33 million individuals of all ages, with a particular impact on infants, young children, older adults, and immunocompromised individuals.

Virex is working on antiviral therapies for its unique inhaled antiviral nanoemulsion treatment for RSV. The results have shown promising results, marking a significant milestone in the development of a potential breakthrough therapy.

It is a major cause of bronchiolitis and pneumonia, leading to 3 million hospitalisations and 60,000-200,000 in-hospital deaths in children aged under 5 years, worldwide.

RSV has been a challenging infection with the market projected to be US$4B in 2027. Despite the urgent need for effective treatments, there are currently limited therapeutic options available.

These latest results have indicated GlyXine, Virex Pharma’s proprietary antiviral nanoemulsion has a therapeutic index that is significantly higher than those reported by Ventolin and other inhaled corticosteroid products. This provides additional reassurance of the potential safety of the GlyXine product.

GlyXine has exhibited remarkable potential in inhibiting RSV replication within human cells. The in vitro results provide a strong foundation for further development and pave the way for upcoming animal trials.

Virex Pharma completes studies for its inhaled antiviral treatment
Rolee Kumar, CEO

“We are extremely encouraged by the results of the in vitro studies, which demonstrate the antiviral activity and safety profile of GlyXine” said Ms Rolee Kumar, CEO of Virex.

RSV poses a significant public health challenge, particularly for vulnerable populations. Our innovative inhaled antiviral treatment has the potential to transform the treatment landscape for RSV, offering a targeted and convenient therapeutic option.

Rolee Kumar, CEO

With the completion of the in vitro studies, Virex will now focus on initiating comprehensive preclinical and clinical studies to evaluate the safety, efficacy, and tolerability of GlyXine in animals and human subjects. These pivotal trials will provide crucial insights into the therapeutic potential of Virex’s innovative inhaled antiviral treatment for RSV.

~~

Get more advice and actionable insights to help you grow your startup.

Share this post :

LinkedIn
Twitter
Facebook
Picture of Joyce Guan

Joyce Guan

Latest News

Become a Startup Insider

Get the latest startup news, tips, and inspiration in your inbox each week.